New Antimicrobials Hailed as a 'Major Shift' in Combating Antibiotic-Resistant Gonorrhoea

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with estimates suggesting in excess of 82 million infections each year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". A tracking program revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to see it through.

“This authorization marks a major breakthrough in the treatment of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Data and Worldwide Availability

According to data published in a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which involves a dual-drug approach. The study involved hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in many low-income and middle-income countries.

Medical professionals on the front lines have voiced positive views. Access to a single-dose, oral treatment like this is seen as a "revolutionary step" for gonorrhoea control. This is considered essential to reduce the burden of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.